Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q.M. Chow, Tanguy Y. Seiwert, Robert I. Haddad et al.|Journal of Clinical Oncology|2016Cited by 859
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Robert I. Haddad, Tanguy Y. Seiwert et al.|British Journal of Cancer|2018Cited by 457
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancerElena Garralda, Gerald S. Falchook, Ammar Sukari et al.|ESMO Open|2022Cited by 87
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009Eric Van Cutsem, Josep Tabernero, M. Dicato et al.|Annals of Oncology|2010Cited by 80
A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.Elena Garralda, Gerald S. Falchook, Ammar Sukari et al.|Journal of Clinical Oncology|2021Cited by 46